It is a multicenter, national, randomized 1:1 ratio, controlled, parallel, open study. Patients with severe ARDS-CoVid19 will be included in the trial within the first 24 hours. Patients will be randomized to one of the treatment groups: - SEV group: 25 patients with Sevoflurane sedation by inhalation, starting at 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved (BIS 40-50) - PRO group: 25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
Drug: Sevoflurane
25 patients sedated with Sevoflurane via inhalation, starting with 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
Drug: Propofol
25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
Inclusion Criteria:
- Age 18 years or more.
- Diagnosis of Acute Respiratory Distress Syndrome caused by COVID19 infection.
- Signature of Patient's Consent or Verbal Consent of Legal Representative
Exclusion Criteria:
- Intracranial hypertension
- Hypersensitivity to the active ingredient (propofol or sevoflurane) or to any of the
excipients
- Current volume < 250ml
- History of malignant hyperthermia
- Liver failure
- Neutropenia (<0.5x109)
- Pregnant or lactating women
- Have received chemotherapy in the last month since their inclusion in the study
Hospital Universitario Cruces
Barakaldo, Bizkaia, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain
Hospital General Universitario de Valencia
Valencia, Spain